Clinical Evaluation of Dicumarinyl Derivatives with a Metabolic Study of the Radioactively Labeled Anticoagulants in Animals
Authors:
- Eric P. HausnerEHEric P. Hausner
- Charles L. ShaferCSCharles L. Shafer
- Marion CorsonMCMarion Corson
- Ogden JohnsonOJOgden Johnson
- Theodore TrujilloTTTheodore Trujillo
- Wright LanghamWLWright Langham
- 1 February 1951
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation
- Vol. 3 (2) , 171-181
Abstract
The common use of dicumarinyl derivatives for the treatment of thromboembolic diseases justifies further clinical evaluation of dicumarol and 4,4'-dihydroxydicumarinyl ethyl acetate [Pelentan, Tromexan, 3,3'-carboxymethylenebis (4-hydroxycoumarin) ethyl ester.] The need for a more thorough understanding of the pharmacodynamic action of dicumarinyl anticoagulants has prompted a study of their gross metabolism in animals, using C 14 -labeled materials.Keywords
This publication has 3 references indexed in Scilit:
- The Quantitative Determination of C14 Activity in Biological Systems by Direct Plating1Journal of the American Chemical Society, 1948
- Techniques in Using Carbon 14Analytical Chemistry, 1947
- Qualitative analysis of proteins: a partition chromatographic method using paperBiochemical Journal, 1944